- Home
- UAN vs NUVB Comparison
UAN vs NUVB Comparison
Compare UAN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- NUVB
- Stock Information
- Founded
- UAN 2007
- NUVB 2018
- Country
- UAN United States
- NUVB United States
- Employees
- UAN N/A
- NUVB N/A
- Industry
- UAN Agricultural Chemicals
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- NUVB Health Care
- Exchange
- UAN Nasdaq
- NUVB Nasdaq
- Market Cap
- UAN 1.0B
- NUVB 1.1B
- IPO Year
- UAN 2011
- NUVB N/A
- Fundamental
- Price
- UAN $100.10
- NUVB $4.71
- Analyst Decision
- UAN
- NUVB Strong Buy
- Analyst Count
- UAN 0
- NUVB 7
- Target Price
- UAN N/A
- NUVB $8.86
- AVG Volume (30 Days)
- UAN 29.0K
- NUVB 9.3M
- Earning Date
- UAN 10-29-2025
- NUVB 11-03-2025
- Dividend Yield
- UAN 6.79%
- NUVB N/A
- EPS Growth
- UAN 141.96
- NUVB N/A
- EPS
- UAN 12.04
- NUVB N/A
- Revenue
- UAN $614,528,000.00
- NUVB $26,748,000.00
- Revenue This Year
- UAN N/A
- NUVB $283.17
- Revenue Next Year
- UAN N/A
- NUVB $340.98
- P/E Ratio
- UAN $8.23
- NUVB N/A
- Revenue Growth
- UAN 16.52
- NUVB 1137.19
- 52 Week Low
- UAN $63.45
- NUVB $1.54
- 52 Week High
- UAN $99.77
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- UAN 74.78
- NUVB 57.55
- Support Level
- UAN $91.44
- NUVB $3.92
- Resistance Level
- UAN $95.00
- NUVB $5.17
- Average True Range (ATR)
- UAN 2.03
- NUVB 0.46
- MACD
- UAN 0.78
- NUVB -0.03
- Stochastic Oscillator
- UAN 92.93
- NUVB 56.78
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.